StreetAlpha.app
Home › Stocks › RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Healthcare
$16.70
▲ +5.03%
LAST CLOSE · NOV 17

Ultragenyx is a pharmaceutical company in Novato, California, developing drug and gene therapy candidates for disease states. It last closed at $16.70 on Nov 17, up 5.03% on the day. RARE reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 15 analysts is $24.53 (+46.9% from the last close), with a high of $39.00 and a low of $16.00. Analyst consensus is Hold, based on the latest ratings from 15 firms (7 buy, 8 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in RARE, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $2.5M, the largest $2.5M.

AI Auto Pilots
Is RARE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$730.0M
+15.8% vs a year ago
Net income
−$524.0M
−71.8% margin
EPS (diluted)
−$5.17
Free cash flow
−$442.0M
−60.5% margin
Valuation
Market cap
$1.7B
101.9M shares
P/E
–
No P/E while losing money
Price to sales
2.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$150.0M
At Sep 30
Shareholder equity
−$376.0M
Shares outstanding
101.9M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $351.4M$351.4MFY2021FY2022: $363.3M$363.3MFY2022FY2023: $434.0M$434.0MFY2023FY2024: $560.0M$560.0MFY2024FY2025: $673.0M$673.0MFY2025

From RARE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
$2.37
$226.6M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 15 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
15firms
7 Buy8 Hold0 Sell
Each firm's latest rating on RARE in the past 90 days
Average 12-month target
$24.53
▲ 46.9% upside

Based on 15 analysts who set a price target on RARE in the past 90 days. The average target is $24.53, with a high of $39.00 and a low of $16.00, compared with the last close of $16.70.

$11$21$31$41PAST 31 TRADING DAYS12-MONTH TARGETSHIGH $39AVG $24.53LOW $16Jul 1LAST CLOSE+12 MO$11$21$31$41PAST 31 DAYSTARGETSHIGH $39AVG $24.53LOW $16Jul 1LAST CLOSE+12 MO
Highest target$39.00
Average target$24.53
Lowest target$16.00
Latest rating changes
CitigroupTarget lowered
Nov 5Buy$32 → $22
Canaccord GenuityTarget lowered
Nov 4Buy$39 → $34
TD CowenTarget raised
Nov 4Buy$18 → $19
Morgan StanleyTarget raised
Nov 4Hold$20 → $22
Goldman SachsTarget lowered
Nov 4Hold$19 → $17
DateFirmActionRatingPrice target
Nov 5CitigroupTarget loweredBuy$32 → $22
Nov 4Canaccord GenuityTarget loweredBuy$39 → $34
Nov 4TD CowenTarget raisedBuy$18 → $19
Nov 4Morgan StanleyTarget raisedHold$20 → $22
Nov 4Goldman SachsTarget loweredHold$19 → $17
Loading…

Technical Analysis

RARE · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 2% above its 20 day and 8% above its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 54). The nearest support is the Pivot at $16.36, and the nearest resistance the swing high (Nov 11) at $16.77.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 5.2%/day
Key levels
$39.8952 week high+138.9%
$22.45200 day average+34.4%
$21.37100 day average+28.0%
$17.08Pivot R1+2.3%
$16.77Swing high (Nov 11)+0.4%
$16.70Last close
$16.36Pivot−2.0%
$16.2920 day average−2.5%
$15.99Pivot S1−4.3%
$15.3450 day average−8.1%
$15.12Swing low (Nov 6)−9.5%
$12.7352 week low−23.8%
Indicators
RSI (14)53.84Middle of its rangeNeutral
MACD0.05Above its signal lineBullish
Stochastic43.6Middle of its rangeNeutral
ADX (14)16.4No clear trend
Williams %R-37.8Oversold below −80, overbought above −20Neutral
CCI (20)18.6Oversold below −100, overbought above 100Neutral
Rate of change+0.4%Change over 10 sessionsBullish
ATR (14)$0.86Typical daily range, 5.2% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for RARE

What happened before

See how RARE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RARE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RARE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 23 – Sep 23
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$2.5M
Largest print
$2.5M
Loading…

RARE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●154 buying vs 167 selling
  • ▼Held by funds -2.0 pts
  • ▼Funds holding -45
  • ▲Superinvestors: 4 added, 1 cut
  • ▲Put/call 1.10 to 0.26
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding267312−14.4%
In funds' top 1048−50.0%
Held by funds102.9%104.9%−2.0 pts
New / increased45 / 10957 / 116−11.0%
Reduced / sold out84 / 8398 / 47+15.2%
Put/call ratio0.261.10−76.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RARE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RARE is in one of them and how their past RARE trades turned out.

RARE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RARE in an article yet. Here's the latest on the wider market.

RARE Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Oct 12
Who traded RARE · since 2021
Latest 5 filings of 8
$1K – $15KTraded Sep 29, 2026Filed Oct 12, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Feb 18, 2026Filed Mar 9, 2026
$1K – $15KTraded Aug 8, 2025Filed Sep 12, 2025
$1K – $15KTraded Jul 15, 2025Filed Aug 14, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KSep 29, 2026Oct 12, 202613 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KFeb 18, 2026Mar 9, 202619 d
Gilbert CisnerosD · CABuy$1K – $15KAug 8, 2025Sep 12, 202535 d
Gilbert CisnerosD · CABuy$1K – $15KJul 15, 2025Aug 14, 202530 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Ultragenyx Pharmaceutical

Ultragenyx is a pharmaceutical company based in Novato, California. It is developing drug candidates, including gene therapy candidates that use AAV vectors, for a range of disease states. Its work is aimed at patients, physicians and healthcare providers who would use any approved treatments, and it works with regulators such as the FDA and the EMA to define approval paths.

Headquarters
Novato, CA